Rapid isolation of pan-neutralizing antibodies against Omicron variants from convalescent individuals infected with SARS-CoV-2
IntroductionThe emergence of SARS-CoV-2 Omicron subvariants has presented a significant challenge to global health, as these variants show resistance to most antibodies developed early in the pandemic. Therapeutic antibodies with potent efficacy to the Omicron variants are urgently demanded.MethodsU...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1374913/full |
| _version_ | 1797272640352681984 |
|---|---|
| author | Peng Yu Jingping Ran Jingping Ran Ruiqi Yang Hang Zhu Song Lu Yuzhang Wu Tingting Zhao Tingting Zhao Tianchen Xiong |
| author_facet | Peng Yu Jingping Ran Jingping Ran Ruiqi Yang Hang Zhu Song Lu Yuzhang Wu Tingting Zhao Tingting Zhao Tianchen Xiong |
| author_sort | Peng Yu |
| collection | DOAJ |
| description | IntroductionThe emergence of SARS-CoV-2 Omicron subvariants has presented a significant challenge to global health, as these variants show resistance to most antibodies developed early in the pandemic. Therapeutic antibodies with potent efficacy to the Omicron variants are urgently demanded.MethodsUtilizing the rapid antibody discovery platform, Berkeley Lights Beacon, we isolated two monoclonal neutralizing antibodies, 2173-A6 and 3462-A4. These antibodies were isolated from individuals who recently recovered from Omicron infections.ResultsBoth antibodies, 2173-A6 and 3462-A4, demonstrated high affinity for the RBD and effectively neutralized pseudoviruses from various Omicron lineages, including BA.4/5, XBB.1.16, XBB.1.5, and EG.5.1. This neutralization was achieved through binding to identical or overlapping epitopes.DiscussionThe use of the Beacon platform enabled the rapid isolation and identification of effective neutralizing antibodies within less than 10 days. This process significantly accelerates the development of novel therapeutic antibodies, potentially reducing the time required to respond to unknown infectious diseases in the future. |
| first_indexed | 2024-03-07T14:32:15Z |
| format | Article |
| id | doaj.art-b3f51cc9375f432fa6f7accf1aa604f1 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-07T14:32:15Z |
| publishDate | 2024-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-b3f51cc9375f432fa6f7accf1aa604f12024-03-06T04:23:03ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-03-011510.3389/fimmu.2024.13749131374913Rapid isolation of pan-neutralizing antibodies against Omicron variants from convalescent individuals infected with SARS-CoV-2Peng Yu0Jingping Ran1Jingping Ran2Ruiqi Yang3Hang Zhu4Song Lu5Yuzhang Wu6Tingting Zhao7Tingting Zhao8Tianchen Xiong9Antibody Research Platform, Chongqing International Institute for Immunology, Chongqing, ChinaAntibody Research Platform, Chongqing International Institute for Immunology, Chongqing, ChinaSchool of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, ChinaAntibody Research Platform, Chongqing International Institute for Immunology, Chongqing, ChinaAntibody Research Platform, Chongqing International Institute for Immunology, Chongqing, ChinaAntibody Research Platform, Chongqing International Institute for Immunology, Chongqing, ChinaAntibody Research Platform, Chongqing International Institute for Immunology, Chongqing, ChinaAntibody Research Platform, Chongqing International Institute for Immunology, Chongqing, ChinaSchool of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, ChinaAntibody Research Platform, Chongqing International Institute for Immunology, Chongqing, ChinaIntroductionThe emergence of SARS-CoV-2 Omicron subvariants has presented a significant challenge to global health, as these variants show resistance to most antibodies developed early in the pandemic. Therapeutic antibodies with potent efficacy to the Omicron variants are urgently demanded.MethodsUtilizing the rapid antibody discovery platform, Berkeley Lights Beacon, we isolated two monoclonal neutralizing antibodies, 2173-A6 and 3462-A4. These antibodies were isolated from individuals who recently recovered from Omicron infections.ResultsBoth antibodies, 2173-A6 and 3462-A4, demonstrated high affinity for the RBD and effectively neutralized pseudoviruses from various Omicron lineages, including BA.4/5, XBB.1.16, XBB.1.5, and EG.5.1. This neutralization was achieved through binding to identical or overlapping epitopes.DiscussionThe use of the Beacon platform enabled the rapid isolation and identification of effective neutralizing antibodies within less than 10 days. This process significantly accelerates the development of novel therapeutic antibodies, potentially reducing the time required to respond to unknown infectious diseases in the future.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1374913/fullSARS-CoV-2COVID-19Omicronneutralizing antibodybeacon |
| spellingShingle | Peng Yu Jingping Ran Jingping Ran Ruiqi Yang Hang Zhu Song Lu Yuzhang Wu Tingting Zhao Tingting Zhao Tianchen Xiong Rapid isolation of pan-neutralizing antibodies against Omicron variants from convalescent individuals infected with SARS-CoV-2 Frontiers in Immunology SARS-CoV-2 COVID-19 Omicron neutralizing antibody beacon |
| title | Rapid isolation of pan-neutralizing antibodies against Omicron variants from convalescent individuals infected with SARS-CoV-2 |
| title_full | Rapid isolation of pan-neutralizing antibodies against Omicron variants from convalescent individuals infected with SARS-CoV-2 |
| title_fullStr | Rapid isolation of pan-neutralizing antibodies against Omicron variants from convalescent individuals infected with SARS-CoV-2 |
| title_full_unstemmed | Rapid isolation of pan-neutralizing antibodies against Omicron variants from convalescent individuals infected with SARS-CoV-2 |
| title_short | Rapid isolation of pan-neutralizing antibodies against Omicron variants from convalescent individuals infected with SARS-CoV-2 |
| title_sort | rapid isolation of pan neutralizing antibodies against omicron variants from convalescent individuals infected with sars cov 2 |
| topic | SARS-CoV-2 COVID-19 Omicron neutralizing antibody beacon |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1374913/full |
| work_keys_str_mv | AT pengyu rapidisolationofpanneutralizingantibodiesagainstomicronvariantsfromconvalescentindividualsinfectedwithsarscov2 AT jingpingran rapidisolationofpanneutralizingantibodiesagainstomicronvariantsfromconvalescentindividualsinfectedwithsarscov2 AT jingpingran rapidisolationofpanneutralizingantibodiesagainstomicronvariantsfromconvalescentindividualsinfectedwithsarscov2 AT ruiqiyang rapidisolationofpanneutralizingantibodiesagainstomicronvariantsfromconvalescentindividualsinfectedwithsarscov2 AT hangzhu rapidisolationofpanneutralizingantibodiesagainstomicronvariantsfromconvalescentindividualsinfectedwithsarscov2 AT songlu rapidisolationofpanneutralizingantibodiesagainstomicronvariantsfromconvalescentindividualsinfectedwithsarscov2 AT yuzhangwu rapidisolationofpanneutralizingantibodiesagainstomicronvariantsfromconvalescentindividualsinfectedwithsarscov2 AT tingtingzhao rapidisolationofpanneutralizingantibodiesagainstomicronvariantsfromconvalescentindividualsinfectedwithsarscov2 AT tingtingzhao rapidisolationofpanneutralizingantibodiesagainstomicronvariantsfromconvalescentindividualsinfectedwithsarscov2 AT tianchenxiong rapidisolationofpanneutralizingantibodiesagainstomicronvariantsfromconvalescentindividualsinfectedwithsarscov2 |